08:51 AM EDT, 09/03/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) , which is advancing therapeutic options for sepsis and septic shock, said on Tuesday that 129 patients are now participating in its Tigris trial. Spectral, which is aiming for 150 trial participants, expects to complete enrollment in early December

Tigris is a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a controlled trial of adults treated for endotoxemia and septic shock.

Spectral also reported that its PMX distribution agreement with Baxter will be reassigned after the latter sold its kidney care business (to be renamed Vantive) to the Carlyle Group for US$3.8 billion.